))
Diversity Matters in Clinical Trials
Manage episode 472046617 series 3506216
Content provided by Darshan Kulkarni. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Darshan Kulkarni or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this insightful discussion, Shuja Naqvi, CEO of Biopharma Informatics, joins Darshan Kulkarni to explore the evolving landscape of clinical research. Shuja shares how his company has expanded across seven states, strategically choosing locations to promote diversity—not just in ethnicity, but also in socioeconomic and regional representation. He highlights the importance of gathering data from various populations to improve the effectiveness and inclusivity of clinical trials.
They delve into the growing role of research as a care option, particularly for uninsured patients who, through clinical trial participation, gain access to free medical care, medications, and life-saving screenings. While this model presents clear benefits, it also raises ethical concerns, such as the potential for undue influence when patients rely on trials for necessary healthcare. Shuja emphasizes the role of informed consent and IRB oversight in ensuring that participation remains voluntary and ethical.
The conversation also addresses compensation for trial participants. Shuja argues that current payments are insufficient, considering the risks involved in testing non-FDA-approved treatments. He stresses that researchers should ask themselves: “Would I enroll my own family in this trial?” If not, it’s a sign that ethical standards and participant compensation need to be reconsidered.
220 episodes
Share
